S-1/A: Biofrontera Inc. Announces Common Stock and Warrant Offering to Bolster Capital

Biofrontera Inc. is offering up to 3,300,000 shares of common stock and warrants in a best efforts offering to raise capital for general corporate purposes.

Summary

• Biofrontera Inc. is offering up to 3,300,000 shares of its common stock and up to 3,300,000 warrants to purchase common stock.
• The offering also includes pre-funded warrants for purchasers who would exceed beneficial ownership limits.
• The combined offering price is assumed to be $1.51 per share and accompanying warrant, with a warrant exercise price of $1.51.
• The offer will terminate on February 16, 2024, unless completed sooner or terminated earlier by the company.
• Roth Capital Partners, LLC is acting as the sole placement agent on a reasonable best efforts basis.
• The company intends to use the net proceeds for general corporate purposes, including working capital and investments in growth strategies.
• Preliminary results for the fiscal year ended December 31, 2023, estimate total revenues between $33.8 million and $34.3 million, and a net loss between $20.3 million and $21.3 million.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The capital raise is a positive step, but the company's history of losses and the competitive landscape create uncertainty.

Positives

• The offering aims to strengthen the company's financial position.
• The company has a commercial team and generates revenue by selling licensed products directly to dermatology offices and groups.
• The company has a new formulation of Ameluz that lacks propylene glycol and reduces the accumulation of certain contaminants over time.

Negatives

• The company has a history of operating losses and anticipates continuing to incur losses.
• The offering is on a best efforts basis, and there is no guarantee that all securities will be sold.
• The company's stockholders equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2023 was $1,038,000, and the company is no longer in compliance with the continued listing requirement under Nasdaq Listing Rule 5550(b)(1).

Risks

• The company's sole source of revenue is from sales of licensed products, primarily Ameluz.
• Generic versions of Ameluz may enter the market, potentially reducing its price and market share.
• The company is dependent on its collaboration with the Ameluz Licensor and Ferrer for the supply and development of its licensed products.
• Insurance coverage and medical expense reimbursement may be limited for the company's licensed products.
• Healthcare legislative changes may have a material adverse effect on the company's business and results of operations.
• The company faces significant competition from other pharmaceutical and medical device companies.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company previously identified a material weakness in its internal control over financial reporting.
• Biofrontera AG beneficially owns approximately 23.7% of the company's outstanding shares of common stock and will be able to exert significant control over matters subject to stockholder approval.

Future Outlook

The company believes that the net proceeds from this offering, together with its cash on hand and other strategic initiatives, will satisfy its capital needs until mid-2024.

Industry Context

The company operates in the biopharmaceutical industry, focusing on dermatological conditions, specifically actinic keratoses and impetigo. It competes with other pharmaceutical and medical device companies, as well as existing treatments like cryotherapy.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees' job security is dependent on the company's ability to secure funding and execute its business plan.
• Customers may benefit from the company's continued investment in its products and services.
• Suppliers and creditors are subject to the company's ability to meet its financial obligations.

Next Steps

• Complete the offering and receive the net proceeds.
• Utilize the net proceeds for general corporate purposes, including working capital and investments in growth strategies.
• Continue to monitor the impact of the supply chain on the business and ensure the stability of the supply chains for Ameluz and BF-RhodoLED.

Key Dates

Keywords

warrants, common stock, offering, Biofrontera, Ameluz, Securities